Sugi Predict

Sugi Predict / Compounds / SCHEMBL1852602

SCHEMBL1852602

SCHEMBL1852602

CS(=O)(=O)Cc1ccc(N)c(I)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 5/20 0.48
▸ CA1 P00915 4/20 0.48
▸ CA9 Q16790 3/20 0.48
▸ CA5A P35218 2/20 0.48
▸ CA12 O43570 1/20 0.48
▸ CA4 P22748 1/20 0.48
▸ CA6 P23280 1/20 0.48
▸ CA7 P43166 1/20 0.48
▸ CA14 Q9ULX7 1/20 0.48
▸ CA5B Q9Y2D0 1/20 0.48
▸ BRD4 O60885 1/20 0.40
▸ ADRB2 P07550 1/20 0.38
▸ TBXA2R P21731 1/20 0.38
▸ G6PD P11413 1/20 0.34
▸ IDE P14735 1/20 0.34
▸ PTPN1 P18031 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.32
▸ SLC6A3 Q01959 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ GAA P10253 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21550114 0.85 CA2 (0.50) CA2CA1CA9CA5ACA12
SCHEMBL4347849 0.82 CA1 (0.43) CA2CA1CA9CA5ACA12
SCHEMBL1654641 0.78 SKP2 (0.52) CA2CA1CA9CA5ACA12
SCHEMBL7450435 0.77 CA2 (0.50) CA2CA1CA9CA5ACA12
SCHEMBL18398223 0.77 CA1 (0.48) CA2CA1CA9CA5ACA12
SCHEMBL6108514 0.75 NOS3 (0.42) CA2CA1CA9CA5ACA12
SCHEMBL3640220 0.75 HPGD (0.51) CA2CA1CA9CA5ACA12
SCHEMBL1299504 0.74 GAA (0.54) CA2CA1CA9CA5ACA12
SCHEMBL2206633 0.74 ALDH1A1 (0.65) CA2CA1CA9CA5ACA12
SCHEMBL27037484 0.73 ALDH1A1 (0.53) CA2CA1CA9CA12BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158039-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2023-05-25 — — US disclosed
US-20210236508-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2021-08-05 — — US disclosed
US-20210070756-A1 TETRACYCLIC BROMODOMAIN INHIBITORS ABBVIE INC (US) 2021-03-11 — — US disclosed
US-20200291027-A1 TETRACYCLIC BROMODOMAIN INHIBITORS ABBVIE INC (US) 2020-09-17 — — US disclosed
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 — — US disclosed
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 — — US disclosed
EP-3539960-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) 2019-09-18 — — EP disclosed
EP-3539960-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) 2019-09-18 — — EP disclosed
EP-3539962-A1 TETRACYCLIC BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2019-09-18 — — EP disclosed
EP-2970330-B1 TETRACYCLIC BROMODOMAIN INHIBITORS ABBVIE INC (US) 2019-04-17 — — EP disclosed
US-20140162971-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2014-06-12 — — US disclosed
WO-2013097601-A1 BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2013-07-04 — — WO disclosed
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 — — US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 — — EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 — — US disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 — — EP disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 — — WO disclosed
US-5583149-A TREATING VASCULAR HEADACHES BRISTOL-MYERS SQUIBB COMPANY (US) 1996-12-10 — — US disclosed
US-5468768-A FOR TREATING VASCULAR HEADACHES BRISTOL-MYERS SQUIBB COMPANY (US) 1995-11-21 — — US disclosed
EP-0666258-A1 Indolylcycloaklanylamin- und Indolylcycloalkenylamine derivatives, their preparation and their use as anti-migraine agents Bristol-Myers Squibb Company (US) 1995-08-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200291027-A1 TETRACYCLIC BROMODOMAIN INHIBITORS BRD3, BRD4, BRD1 CA2 2280/4885CA1 1983/4885CA9 2560/4885
US-20210070756-A1 TETRACYCLIC BROMODOMAIN INHIBITORS BRD3, BRD4, BRD1 CA2 2280/4885CA1 1983/4885CA9 2560/4885
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF MYC, BRD1, BRD3 CA2 4677/4885CA1 4734/4885CA9 4749/4885
US-20140162971-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 CA2 2735/4885CA1 1571/4885CA9 2823/4885
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA CA2 1618/4885CA1 4251/4885CA9 2541/4885
US-20230158039-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 CA2 2735/4885CA1 1571/4885CA9 2823/4885
US-20210236508-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 CA2 2735/4885CA1 1571/4885CA9 2823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.